Cancer

• 

  Publication Venue For

  • Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course..  129:367-375. 2023
  • Time to cancer treatment and reproductive outcomes after fertility preservation among adolescent and young adult women with cancer..  129:307-319. 2023
  • Solidifying roles, responsibilities, and the process of navigation across the continuum of cancer care: The Professional Oncology Navigation Task Force..  128 Suppl 13:2669-2672. 2022
  • Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer..  128:819-827. 2022
  • Active surveillance for intermediate-risk prostate cancer in African American and non-Hispanic White men..  127:4403-4412. 2021
  • Delays in breast cancer care by race and sexual orientation: Results from a national survey with diverse women in the United States..  127:3514-3522. 2021
  • Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy..  127:2980-2989. 2021
  • Validation of an oncology-specific opioid risk calculator in cancer survivors..  127:1529-1535. 2021
  • Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer..  127:957-967. 2021
  • "This is some mess right here": Exploring interactions between Black sexual minority women and health care providers for breast cancer screening and care..  127:74-81. 2021
  • Material and psychological financial hardship related to employment disruption among female adolescent and young adult cancer survivors..  127:137-148. 2021
  • Obesity, race, and long-term prostate cancer outcomes..  126:3733-3741. 2020
  • Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer..  126:3274-3280. 2020
  • An evolutionary framework for treating pediatric sarcomas..  126:2577-2587. 2020
  • Patient-hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study..  126:1306-1314. 2020
  • Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database..  125:4003-4010. 2019
  • Poorly controlled diabetes increases the risk of metastases and castration-resistant prostate cancer in men undergoing radical prostatectomy: Results from the SEARCH database..  125:2861-2867. 2019
  • The effects of a randomized trial of brief forms of stress management on RAGE-associated S100A8/A9 in patients with breast cancer undergoing primary treatment..  125:1717-1725. 2019
  • Androgen deprivation therapy and depression in men with prostate cancer treated with definitive radiation therapy..  125:1070-1080. 2019
  • Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?.  125:434-441. 2019
  • Impact of time to testosterone rebound and comorbidity on the risk of cause‐specific mortality in men with unfavorable‐risk prostate cancer.  124:1391-1399. 2018
  • Quality of life after surgery for intracranial meningioma..  124:161-166. 2018
  • C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy.  123:4411-4418. 2017
  • Race and risk of metastases and survival after radical prostatectomy: Results from the SEARCH database..  123:4199-4206. 2017
  • County-level cumulative environmental quality associated with cancer incidence..  123:2901-2908. 2017
  • Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer..  123:1528-1535. 2017
  • Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer..  122:3848-3855. 2016
  • Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men..  122:3564-3575. 2016
  • Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database..  122:222-229. 2016
  • Are lifestyle behavioral factors associated with health-related quality of life in long-term survivors of non-Hodgkin lymphoma?.  121:3343-3351. 2015
  • Cancer survivors' uptake and adherence in diet and exercise intervention trials: an integrative data analysis..  121:77-83. 2015
  • Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: A population-based study.  120:1338-1344. 2014
  • Annual financial impact of well-differentiated thyroid cancer care in the United States..  120:1345-1352. 2014
  • Randomized clinical trial of therapeutic music video intervention for resilience outcomes in adolescents/young adults undergoing hematopoietic stem cell transplant: a report from the Children's Oncology Group..  120:909-917. 2014
  • A multisite, community oncology-based randomized trial of a brief educational intervention to increase communication regarding complementary and alternative medicine..  119:3514-3522. 2013
  • Costs and outcomes evaluation of patient navigation after abnormal cancer screening: Evidence From the Patient Navigation Research Program 2013
  • Erratum: Survivorship navigation outcome measures: A report from the ACS Patient Navigation Working Group on Survivorship Navigation (Cancer (2011) 117 (3575-84)).  118:5450. 2012
  • Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung..  118:1032-1039. 2012
  • Reply to risk of mortality in patients with cancer who experience febrile neutropenia.  117:5246. 2011
  • Research challenges in adolescent and young adult cancer survivor research..  117:2295-2300. 2011
  • The cancer is over, now what?: Understanding risk, changing outcomes..  117:2250-2257. 2011
  • Impact of insurance type on survivor-focused and general preventive health care utilization in adult survivors of childhood cancer: the Childhood Cancer Survivor Study (CCSS)..  117:1966-1975. 2011
  • Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy..  117:1917-1927. 2011
  • Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis..  117:1334-1349. 2011
  • A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia..  117:1253-1261. 2011
  • p14ARF genetic polymorphisms and susceptibility to second primary malignancy in patients with index squamous cell carcinoma of the head and neck..  117:1227-1235. 2011
  • Association of multi-drug resistance gene polymorphisms with pancreatic cancer outcome..  117:744-751. 2011
  • Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma..  117:734-743. 2011
  • Structural and reliability analysis of a patient satisfaction with cancer-related care measure: a multisite patient navigation research program study..  117:854-861. 2011
  • A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006..  117:526-533. 2011
  • Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction..  117:545-553. 2011
  • Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer..  117:480-491. 2011
  • Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience..  117:250-258. 2011
  • Treatment recommendations for primary extradural meningiomas..  117:24-38. 2011
  • Risk of mortality in patients with cancer who experience febrile neutropenia..  116:5555-5563. 2010
  • Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer..  116:5325-5335. 2010
  • Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer..  116:5038-5046. 2010
  • Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience..  116:4711-4717. 2010
  • Genetic variants in selected pre-microRNA genes and the risk of squamous cell carcinoma of the head and neck..  116:4753-4760. 2010
  • Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer..  116:4825-4832. 2010
  • Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer..  116:4095-4102. 2010
  • Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11)..  116:4007-4013. 2010
  • The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function..  116:3807-3814. 2010
  • The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials..  116:3702-3711. 2010
  • Cancer treatment cost in the United States: has the burden shifted over time?.  116:3477-3484. 2010
  • Latitude may modify the effect of TP53 codon 72 polymorphism on cancer risk..  116:3523. 2010
  • A single nucleotide polymorphism in the alcohol dehydrogenase 7 gene (alanine to glycine substitution at amino acid 92) is associated with the risk of squamous cell carcinoma of the head and neck..  116:2984-2992. 2010
  • Association of p53 codon 72 polymorphism with risk of second primary malignancy in patients with squamous cell carcinoma of the head and neck..  116:2350-2359. 2010
  • Angiosarcoma after breast-conserving therapy: long-term outcomes with hyperfractionated radiotherapy..  116:1872-1878. 2010
  • Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma..  116:1938-1946. 2010
  • Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death..  116:1887-1892. 2010
  • Racial differences in the perception of lung cancer: the 2005 Health Information National Trends Survey..  116:1981-1986. 2010
  • Women's experiences with genomic testing for breast cancer recurrence risk..  116:1992-2000. 2010
  • Reply to early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival.  116:1616. 2010
  • Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer..  116:1446-1453. 2010
  • Impact of smoking on patients with stage III colon cancer: results from Cancer and Leukemia Group B 89803..  116:957-966. 2010
  • Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study..  116:974-982. 2010
  • Quantitative assessment of cardiorespiratory fitness, skeletal muscle function, and body composition in adults with primary malignant glioma..  116:695-704. 2010
  • We need better randomized comparison trials of prostate cancer..  116:270-272. 2010
  • Racial differences in follow-up of abnormal mammography findings among economically disadvantaged women..  115:5788-5797. 2009
  • Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer..  115:5637-5650. 2009
  • Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy..  115:5319-5328. 2009
  • Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients..  115:5218-5227. 2009
  • Multimodality therapy for locoregional extrahepatic cholangiocarcinoma: a population-based analysis..  115:5175-5183. 2009
  • Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma..  115:5117-5125. 2009
  • A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma..  115:4766-4774. 2009
  • Partner-assisted emotional disclosure for patients with gastrointestinal cancer: results from a randomized controlled trial..  115:4326-4338. 2009
  • Associations between lifestyle factors and quality of life among older long-term breast, prostate, and colorectal cancer survivors..  115:4001-4009. 2009
  • Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy..  115:3501-3511. 2009
  • Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality..  115:2853-2862. 2009
  • Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry..  115:2971-2979. 2009
  • Health status and quality of life among non-Hodgkin lymphoma survivors..  115:3312-3323. 2009
  • Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia..  115:2922-2929. 2009
  • Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma..  115:2964-2970. 2009
  • Under-representation of women in high-impact published clinical cancer research..  115:3293-3301. 2009
  • Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors..  115:2660-2670. 2009
  • Frequency, nature, effects, and correlates of conflicts of interest in published clinical cancer research..  115:2783-2791. 2009
  • Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy..  115:2104-2110. 2009
  • Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma..  115:2188-2198. 2009
  • Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma..  115:2119-2127. 2009
  • Predictors of inactive lifestyle among adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study..  115:1984-1994. 2009
  • Association of p73 G4C14-to-A4T14 polymorphism with human papillomavirus type 16 status in squamous cell carcinoma of the head and neck in non-Hispanic whites..  115:1660-1668. 2009
  • Preoperative breast magnetic resonance imaging in early breast cancer: implications for partial breast irradiation..  115:1621-1630. 2009
  • Initial report of the cancer Patient-Reported Outcomes Measurement Information System (PROMIS) sexual function committee: review of sexual function measures and domains used in oncology..  115:1142-1153. 2009
  • Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541..  115:1109-1120. 2009
  • Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804..  115:480-488. 2009
  • Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival..  115:581-586. 2009
  • Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export..  115:595-607. 2009
  • Promoting physical activity in childhood cancer survivors: results from the Childhood Cancer Survivor Study..  115:642-654. 2009
  • Stereotactic radiotherapy for pancreatic cancer?.  115:468-472. 2009
  • Treatment of myelodysplastic syndrome with 2 schedules and doses of oral topotecan: a randomized phase 2 trial by the Cancer and Leukemia Group B (CALGB 19803)..  115:84-93. 2009
  • Cancer patient preferences for quality and length of life..  113:3459-3466. 2008
  • National Cancer Institute Patient Navigation Research Program: methods, protocol, and measures..  113:3391-3399. 2008
  • Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study..  113:3430-3439. 2008
  • p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers..  113:3307-3314. 2008
  • Improving understanding of adjuvant therapy options by using simpler risk graphics..  113:3382-3390. 2008
  • Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811..  113:3137-3145. 2008
  • Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite..  113:2687-2694. 2008
  • Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma..  113:2038-2045. 2008
  • Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer..  113:2046-2052. 2008
  • Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium..  113:1953-1968. 2008
  • Commentary on imaging of bronchogenic carcinoma..  113:1755-1759. 2008
  • Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL..  113:1544-1551. 2008
  • Prostate-specific antigen screening among young men in the United States..  113:1315-1323. 2008
  • High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006..  113:293-301. 2008
  • Reply to frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.  113:224. 2008
  • Toward population-based indicators of quality end-of-life care: testing stakeholder agreement..  112:2301-2308. 2008
  • Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study..  112:2071-2079. 2008
  • Active surveillance for early-stage prostate cancer: review of the current literature..  112:1650-1659. 2008
  • A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel..  112:521-526. 2008
  • Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer..  110:2628-2639. 2007
  • Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients..  110:2339-2346. 2007
  • Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer..  110:2260-2268. 2007
  • The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care?.  110:2304-2312. 2007
  • Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia..  110:2321-2330. 2007
  • Diluted and undiluted vitreous cytology specimens have a similar cytodiagnostic yield.  111:433-433. 2007
  • Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial..  110:1708-1714. 2007
  • Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment..  110:1840-1850. 2007
  • Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy..  110:1611-1620. 2007
  • Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer..  110:1478-1484. 2007
  • Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group..  110:1542-1550. 2007
  • A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications..  110:1149-1161. 2007
  • Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma..  110:1059-1067. 2007
  • Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study..  110:965-972. 2007
  • Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck..  110:867-875. 2007
  • Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer..  110:906-910. 2007
  • Exogenous hormone use and meningioma risk: what do we tell our patients?.  110:471-476. 2007
  • National inpatient complications and outcomes after surgery for spinal metastasis from 1993-2002..  110:625-630. 2007
  • X-ray repair cross-complementing group 1 (XRCC1) single-nucleotide polymorphisms and the risk of salivary gland carcinomas..  110:318-325. 2007
  • Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy..  110:47-55. 2007
  • Molecularly targeted therapy for malignant glioma..  110:13-24. 2007
  • Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors..  110:56-61. 2007
  • Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study..  109:2547-2556. 2007
  • Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death..  109:2142-2153. 2007
  • Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire..  109:1914-1922. 2007
  • Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: analysis of Radiation Therapy Oncology Group study 0019..  109:1506-1512. 2007
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression..  109:1499-1505. 2007
  • Polymorphisms of the neuronal and inducible nitric oxide synthase genes and the risk of cutaneous melanoma: a case-control study..  109:1570-1578. 2007
  • Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies..  109:1011-1018. 2007
  • Features of the metabolic syndrome and prostate cancer in African-American men..  109:875-881. 2007
  • Glutathione S-transferase gene polymorphisms and risk and survival of pancreatic cancer..  109:840-848. 2007
  • Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?.  109:477-486. 2007
  • Facilitating research participation and improving quality of life for African American prostate cancer survivors and their intimate partners. A pilot study of telephone-based coping skills training..  109:414-424. 2007
  • Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153..  107:2817-2825. 2006
  • Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients..  107:2866-2872. 2006
  • Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation..  107:2589-2596. 2006
  • Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study..  107:2706-2714. 2006
  • Quality measures for the use of adjuvant chemotherapy and radiation therapy in patients with colorectal cancer: a systematic review..  107:2352-2360. 2006
  • Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study..  107:2291-2297. 2006
  • Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years..  107:2245-2253. 2006
  • Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor..  107:1898-1908. 2006
  • Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102)..  107:1883-1890. 2006
  • A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008..  107:1273-1279. 2006
  • Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors..  107:1383-1390. 2006
  • Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer..  107:1050-1054. 2006
  • Caspase-8 levels correlate with the expression of signal transducer and activator of transcription 1 in high-grade but not lower grade neuroblastoma..  107:824-831. 2006
  • Comprehensive long-term follow-up programs for pediatric cancer survivors..  107:841-848. 2006
  • Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy..  107:712-720. 2006
  • Obesity and survival after radical prostatectomy: A 10-year prospective cohort study..  107:521-529. 2006
  • Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate..  106:2617-2623. 2006
  • Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients..  106:2258-2266. 2006
  • Patterns of exercise across the cancer trajectory in brain tumor patients..  106:2224-2232. 2006
  • Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis..  108:102-109. 2006
  • Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study..  106:1794-1803. 2006
  • Incidence and clinical relevance of abnormal complete blood counts in long-term survivors of childhood cancer..  106:1634-1640. 2006
  • Metastatic patterns in adenocarcinoma..  106:1624-1633. 2006
  • Incidence and clinical significance of morphologically benign-appearing endometrial cells in patients age 40 years or older: the impact of the 2001 Bethesda System..  108:39-44. 2006
  • Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia..  106:941-949. 2006
  • Detection of stool DNA mutations before and after treatment of colorectal neoplasia..  106:277-283. 2006
  • Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review..  106:223-233. 2006
  • Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases..  106:208-213. 2006
  • Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis..  106:4-16. 2006
  • Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee..  106:188-195. 2006
  • Houston AANCART best practices: from vision to synergy to reality..  104:2909-2915. 2005
  • Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study..  104:2822-2829. 2005
  • Developing a cancer-specific geriatric assessment: a feasibility study..  104:1998-2005. 2005
  • Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066..  104:1580-1589. 2005
  • Survival analysis of presumptive prognostic markers among oligodendrogliomas..  104:1693-1699. 2005
  • Caspase 8 is absent or low in many ex vivo gliomas..  104:1487-1496. 2005
  • Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma..  104:1478-1486. 2005
  • Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience..  103:2606-2615. 2005
  • Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin..  103:2485-2490. 2005
  • The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system..  103:2304-2312. 2005
  • Survivors of childhood cancer and their guardians..  103:2171-2180. 2005
  • Body mass index in long-term adult survivors of childhood cancer: a report of the Childhood Cancer Survivor Study..  103:1730-1739. 2005
  • Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B..  103:1670-1675. 2005
  • Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma..  103:1280-1291. 2005
  • Does the number of lymph nodes examined in patients with lymph node-negative breast carcinoma have prognostic significance?.  103:664-671. 2005
  • Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial..  103:749-755. 2005
  • Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma..  103:329-338. 2005
  • Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials..  103:140-147. 2005
  • Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis..  101:2727-2736. 2004
  • Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia..  101:2574-2583. 2004
  • Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia..  101:2584-2592. 2004
  • Effects of cancer history and comorbid conditions on mortality and healthcare use among older cancer survivors..  101:2276-2284. 2004
  • Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis..  101:2351-2362. 2004
  • Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480..  101:2202-2208. 2004
  • Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients..  101:1987-1993. 2004
  • Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy..  101:1569-1574. 2004
  • The incidence of testicular recurrence in boys with acute leukemia treated with total body and testicular irradiation and stem cell transplantation..  101:845-850. 2004
  • Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma..  101:379-384. 2004
  • Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia..  101:370-378. 2004
  • Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma..  101:77-82. 2004
  • Overexpression of synuclein-gamma in pancreatic adenocarcinoma..  101:58-65. 2004
  • Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma..  100:2562-2572. 2004
  • Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma..  100:2408-2414. 2004
  • Diagnostic strategies for unknown primary cancer..  100:1776-1785. 2004
  • Erratum: Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management (Cancer (2004) 100 (228-237)).  100:1993-1994. 2004
  • Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251..  100:1438-1448. 2004
  • Risk perception and concern among brothers of men with prostate carcinoma..  100:1537-1544. 2004
  • Age-related vulnerabilities of older adults with colon adenomas: evidence from Project Prevent..  100:1085-1094. 2004
  • Health care for childhood cancer survivors: insights and perspectives from a Delphi panel of young adult survivors of childhood cancer..  100:843-850. 2004
  • Gamma radiation sensitivity and risk of malignant and benign salivary gland tumors: a pilot case-control analysis..  100:561-567. 2004
  • The cancer screening practices of adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study..  100:631-640. 2004
  • Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management..  100:228-237. 2004
  • A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813..  98:2592-2598. 2003
  • Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma..  98:2402-2409. 2003
  • Decision science and cervical cancer..  98:2003-2008. 2003
  • The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States..  98:1987-1994. 2003
  • Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?.  98:1745-1748. 2003
  • Cytologic distinction of goiterous nodules from morphologically normal thyroid: analyses of cytomorphologic features..  99:217-222. 2003
  • Cytopathology of mesenchymal chondrosarcomas: a report and comparison of four patients..  99:211-216. 2003
  • Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy..  98:679-689. 2003
  • Myoid differentiation and prognosis in adult pleomorphic sarcomas of the extremity: an analysis of 92 cases..  98:805-813. 2003
  • A pilot Phase II trial of concurrent radiotherapy, chemotherapy, and hyperthermia for locally advanced cervical carcinoma..  98:277-282. 2003
  • Megestrol acetate in pediatric oncology patients may lead to severe, symptomatic adrenal suppression..  98:397-405. 2003
  • A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma..  98:94-99. 2003
  • Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation..  98:24-30. 2003
  • The correlation between patient characteristics and expectations of benefit from Phase I clinical trials..  98:166-175. 2003
  • Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B..  97:2480-2486. 2003
  • Introduction: Irinotecan in brain tumors.  97:2351. 2003
  • The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors..  97:2359-2362. 2003
  • Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen..  97:2381-2386. 2003
  • Image-guided and intensity-modulated radiosurgery for patients with spinal metastasis..  97:2013-2018. 2003
  • Overview of bladder cancer trials in the Cancer and Leukemia Group B..  97:2090-2098. 2003
  • Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma..  97:1963-1968. 2003
  • Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study..  97:1499-1506. 2003
  • Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers..  97:1263-1270. 2003
  • Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma..  95:2445-2454. 2002
  • A phase I study of a weekly schedule of paclitaxel and carboplatin in patients with advanced carcinoma..  95:2000-2005. 2002
  • Selective aromatase inhibition for patients with androgen-independent prostate carcinoma..  95:1864-1868. 2002
  • Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas..  95:1354-1365. 2002
  • The long-term clinical course of patients with cutaneous melanoma..  95:1286-1293. 2002
  • Impact of undergoing prostate carcinoma screening on prostate carcinoma-related knowledge and distress..  95:1037-1044. 2002
  • Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials..  95:989-996. 2002
  • Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy..  95:888-895. 2002
  • Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer..  95:275-280. 2002
  • Radical prostatectomy versus radiation therapy for clinically localized prostate carcinoma: the butcher and the baker selling their wares..  95:211-214. 2002
  • Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma..  95:361-376. 2002
  • Fine-needle aspiration cytology of articular and periarticular lesions..  96:157-165. 2002
  • Molecular markers of prognosis in astrocytic tumors..  94:2688-2697. 2002
  • Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma..  94:2534-2541. 2002
  • Prostate carcinoma with testicular or penile metastases. Clinical, pathologic, and immunohistochemical features..  94:2610-2617. 2002
  • Concordance of histopathologic and cytologic grading in musculoskeletal sarcomas: can grades obtained from analysis of the fine-needle aspirates serve as the basis for therapeutic decisions?.  96:83-91. 2002
  • Helping patients with localized prostate carcinoma manage uncertainty and treatment side effects: nurse-delivered psychoeducational intervention over the telephone..  94:1854-1866. 2002
  • Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy..  94:987-996. 2002
  • Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study..  94:665-672. 2002
  • Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases..  94:686-689. 2002
  • Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck..  94:393-397. 2002
  • Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study..  94:552-560. 2002
  • New applications of gemcitabine and future directions in the management of pancreatic cancer.  95:941-945. 2002
  • Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B..  94:181-187. 2002
  • Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening..  92:3051-3055. 2001
  • OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal..  92:2837-2844. 2001
  • Stage distribution in patients with a small (.  92:3051-3055. 2001
  • Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma..  92:2673-2679. 2001
  • Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck..  92:2364-2373. 2001
  • Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma..  92:1650-1655. 2001
  • Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854..  92:207-217. 2001
  • Prognostic significance of the number of lymph nodes examined in patients with lymph node-negative breast carcinoma..  91:2258-2262. 2001
  • Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study..  91:1809-1813. 2001
  • Duration of symptoms prior to diagnosis is related inversely to presenting disease stage in children with medulloblastoma..  91:1444-1450. 2001
  • Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma..  91:1256-1263. 2001
  • De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam..  91:928-939. 2001
  • Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV..  91:983-991. 2001
  • The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma..  91:1063-1065. 2001
  • Use of vitamins, minerals, and nutritional supplements by participants in a chemoprevention trial..  91:1040-1045. 2001
  • Social support as a buffer to the psychological impact of stressful life events in women with breast cancer..  91:443-454. 2001
  • Bladder cancer: race differences in extent of disease at diagnosis..  89:1349-1358. 2000
  • Depression after successful treatment for nonsmall cell lung carcinoma..  89:1172-1179. 2000
  • Positron emission tomography scanning in malignant melanoma..  89:1019-1025. 2000
  • Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma..  89:453-462. 2000
  • Association between initial diagnostic procedure and hysteroscopy and abnormal peritoneal washings in patients with endometrial carcinoma..  90:143-147. 2000
  • Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services..  88:2876-2886. 2000
  • Grading of late effects in young adult survivors of childhood cancer followed in an ambulatory adult setting..  88:1687-1695. 2000
  • Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II..  88:1384-1392. 2000
  • Analysis of prognosis and disease progression after local recurrence of melanoma..  88:1063-1071. 2000
  • A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181..  88:825-834. 2000
  • Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas..  88:674-684. 2000
  • Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique.  88:280-285. 2000
  • Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma..  88:42-49. 2000
  • The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia..  86:2684-2692. 1999
  • Managing hereditary ovarian cancer risk..  86:2517-2524. 1999
  • Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B..  86:1985-1991. 1999
  • Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma..  86:2083-2089. 1999
  • Managing hereditary ovarian cancer risk.  86:1697-1704. 1999
  • Ethical ramifications of alternative means of recruiting research participants from cancer registries..  86:647-651. 1999
  • A prospective comparison of fiberoptic transbronchial needle aspiration and bronchial biopsy for bronchoscopically visible lung carcinoma..  87:129-134. 1999
  • The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: results of the 1992-1994 Patterns of Care Study..  85:2499-2505. 1999
  • Transforming growth factor-beta differentially inhibits epithelial ovarian carcinoma cells from primary and metastatic isolates without up-regulation of p21WAF1..  85:1810-1815. 1999
  • Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients..  85:1586-1592. 1999
  • Topotecan treatment of adults with primary malignant glioma. The Brain Tumor Center at Duke..  85:1160-1165. 1999
  • Acquisition of glutamine synthetase expression in human hepatocarcinogenesis: relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis..  85:819-831. 1999
  • Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?.  85:333-340. 1999
  • Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression..  85:47-57. 1999
  • Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature..  85:58-64. 1999
  • Erratum: Ethical ramifications of alternative means of recruiting research participants from cancer registries (Cancer (1999) 86 (647-651)).  86:2707-. 1999
  • Melanoma of the gallbladder: a review of cases seen at Duke University Medical Center..  85:32-39. 1999
  • Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males..  83:2353-2360. 1998
  • Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey..  83:1362-1368. 1998
  • Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis..  83:1002-1011. 1998
  • The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma..  83:918-924. 1998
  • Sebaceous gland carcinoma: a subtle second malignancy following radiation therapy in patients with bilateral retinoblastoma..  83:767-771. 1998
  • Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina..  83:320-330. 1998
  • Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system..  82:2312-2320. 1998
  • Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B..  82:1578-1584. 1998
  • Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma..  82:874-877. 1998
  • T classification and clivus margin as risk factors for determining locoregional control by radiotherapy of nasopharyngeal carcinoma..  82:261-267. 1998
  • Cancer and the functional status of the elderly..  80:1883-1886. 1997
  • Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress..  80:1936-1944. 1997
  • An agenda for clinical research in geriatrics..  80:1294-1301. 1997
  • The Oncology Geriatric Education Retreat: commentary and conclusions..  80:1354-1356. 1997
  • A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response..  80:401-412. 1997
  • Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients..  80:107-114. 1997
  • Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B..  79:2237-2242. 1997
  • Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease..  79:1641-1645. 1997
  • High risk of breast carcinoma after irradiation of young women with Hodgkin's disease..  79:1203-1210. 1997
  • Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy..  79:952-962. 1997
  • Artificial neural networks improve the accuracy of cancer survival prediction..  79:857-862. 1997
  • Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy..  79:75-80. 1997
  • High dose etoposide-based myeloablative therapy followed by autologous blood progenitor cell rescue in the treatment of multiple myeloma..  78:2502-2509. 1996
  • Psychosocial protocol for childhood cancer. A conceptual model..  78:1345-1356. 1996
  • Is there a correlation between duration of presenting symptoms and stage of medulloblastoma at the time of diagnosis?.  78:874-880. 1996
  • A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma..  78:627-632. 1996
  • Participation in a women's breast cancer risk counseling trial. Who participates? Who declines? High Risk Breast Cancer Consortium..  77:2348-2355. 1996
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935..  77:2393-2399. 1996
  • The genetic attributable risk of breast and ovarian cancer..  77:2318-2324. 1996
  • Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?.  77:1854-1861. 1996
  • Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma..  77:1284-1291. 1996
  • Prostate carcinoma patients upstaged by imaging and treated with irradiation. An outcome-based analysis..  77:1334-1341. 1996
  • Geriatric oncology..  77:1017-1019. 1996
  • Complete remission seven years after treatment for metastatic malignant melanoma..  77:900-902. 1996
  • Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy. Clinical characteristics and treatment related toxicities. The Pediatric Oncology Group..  77:555-562. 1996
  • Molecular basis of endometrial cancer..  76:2034-2040. 1995
  • Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer..  76:1709-1714. 1995
  • Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer..  76:1615-1620. 1995
  • The increasing incidence of malignant gliomas and primary central nervous system lymphoma in the elderly..  76:1634-1642. 1995
  • Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies..  76:860-868. 1995
  • Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma..  76:824-832. 1995
  • Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence..  76:787-796. 1995
  • Timing of weight gain and breast cancer risk..  76:243-249. 1995
  • A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors..  75:2762-2767. 1995
  • A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma..  75:1354-1359. 1995
  • An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia..  75:1176-1181. 1995
  • Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach..  75:451-456. 1995
  • External beam irradiation of prostate cancer. Conformal treatment techniques and outcomes for the 1990.  75:1972-1977. 1995
  • Radiation therapy following radical prostatectomy.  75:1909-1913. 1995
  • The National Cancer Data Base report on prostate cancer..  75:136-138. 1995
  • Relationship of DNA ploidy to histology and prognosis in rhabdomyosarcoma. Comparison of flow cytometry and image analysis..  74:3227-3233. 1994
  • Prediction of breast cancer malignancy using an artificial neural network..  74:2944-2948. 1994
  • Biology of aging as related to cancer..  74:2092-2100. 1994
  • Evaluation of piroxantrone in women with metastatic breast cancer and failure on nonanthracycline chemotherapy..  74:1733-1738. 1994
  • A radiologic syndrome after high dose chemotherapy and autologous bone marrow transplantation, with clinical and pathologic features of systemic candidiasis..  74:1360-1366. 1994
  • Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer..  74:1243-1252. 1994
  • A pilot study of etoposide, vinblastine, and doxorubicin plus involved field irradiation in advanced, previously untreated Hodgkin's disease..  74:159-163. 1994
  • Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites..  74:93-99. 1994
  • Selection factors for local excision or abdominoperineal resection of early stage rectal cancer..  73:2716-2720. 1994
  • Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer..  73:2380-2385. 1994
  • Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer..  73:2337-2343. 1994
  • Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale..  73:2087-2098. 1994
  • OVX1 as a marker for early stage endometrial carcinoma..  73:1855-1858. 1994
  • Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate..  73:1708-1715. 1994
  • High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team..  73:1678-1685. 1994
  • Testicular cancer in blacks. A multicenter experience..  73:388-393. 1994
  • High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer..  73:125-134. 1994
  • The radiographic diagnosis and treatment of paraneoplastic central nervous system disease..  73:168-175. 1994
  • Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy..  72:3156-3173. 1993
  • A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver..  72:2560-2563. 1993
  • Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study..  72:2755-2762. 1993
  • Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer..  72:2433-2440. 1993
  • Results of salvage mastectomy for local recurrence after breast-conserving surgery without radiation therapy..  72:2292. 1993
  • Elective inguinal lymph node irradiation for pelvic carcinomas. The University of Florida experience..  72:2058-2065. 1993
  • Skin melanoma. Cured fraction and survival time as functions of thickness, site, histologic type, age, and sex..  72:1219-1223. 1993
  • Risk factors for Wilms tumor. Report from the National Wilms Tumor Study..  72:938-944. 1993
  • A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study..  72:62-68. 1993
  • Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors..  72:244-248. 1993
  • Syndrome of inappropriate secretion of antidiuretic hormone in a patient with carcinoma of the nasopharynx..  72:299. 1993
  • Clinically localized prostatic carcinoma..  71:3797. 1993
  • Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer..  71:3942-3946. 1993
  • The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate..  71:3993-4001. 1993
  • Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity..  71:3690-3696. 1993
  • Chemotherapy for pilocytic astrocytomas..  71:3165-3172. 1993
  • Resources for care..  71:3216-3217. 1993
  • Variation in body fat distribution and breast cancer risk in the families of patients with breast cancer and control families..  71:2764-2768. 1993
  • Intra-arterial cisplatin with or without radiation in limb-sparing for canine osteosarcoma..  71:2484-2490. 1993
  • A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases..  71:1964-1971. 1993
  • Results of salvage mastectomy for local recurrence after breast-conserving surgery without radiation therapy..  71:1774-1779. 1993
  • Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels..  71:1821-1827. 1993
  • Cell growth regulation in epithelial ovarian cancer..  71:1597-1601. 1993
  • Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications..  71:959-969. 1993
  • Growth regulation and transformation of ovarian epithelium..  71:545-551. 1993
  • The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy..  71:493-509. 1993
  • Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type..  71:117-123. 1993
  • Mantle zone lymphoma in a gastric glomus tumor..  70:2246-2249. 1992
  • Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer..  70:2137-2142. 1992
  • Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia..  70:2208-2213. 1992
  • Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma..  70:2073-2076. 1992
  • The annual risk of melanoma progression. Implications for the concept of cure..  70:1917-1927. 1992
  • Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma..  70:1115-1123. 1992
  • Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial..  69:2826-2830. 1992
  • Absence of correlation between nuclear morphometry and survival in stage I non-small cell lung carcinoma..  69:2454-2457. 1992
  • Influence of age, prior abdominal surgery, fraction size, and dose on complications after radiation therapy for squamous cell cancer of the uterine cervix. A patterns of care study..  69:2124-2130. 1992
  • Are there patients with stage I rectal carcinoma at risk for failure after abdominoperineal resection?.  69:1651-1655. 1992
  • Human melanoma-mediated inhibition of autologous CD4+ helper tumor-infiltrating lymphocyte growth in vitro..  69:1843-1849. 1992
  • Syndrome of inappropriate secretion of antidiuretic hormone in a patient with carcinoma of the nasopharynx..  69:1315-1319. 1992
  • A phase II study of piritrexim in patients with advanced squamous head and neck cancer..  69:1008-1011. 1992
  • Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump..  69:920-924. 1992
  • Tumor hormone receptor status and recurrences in premenopausal patients with node-negative breast carcinoma..  69:984-987. 1992
  • Patients with cancer and their spouse caregivers. Perceptions of the illness experience..  69:1074-1079. 1992
  • A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer..  69:327-334. 1992
  • Breast cancer screening behaviors and attitudes in three racial/ethnic groups..  69:165-174. 1992
  • The use of prophylactic eye drops during high-dose cytosine arabinoside therapy..  68:1691-1693. 1991
  • Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy..  68:1501-1506. 1991
  • The role of radical surgery in the management of radiation recurrent and large volume prostate cancer..  68:1265-1271. 1991
  • A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma..  68:965-969. 1991
  • Adenoid cystic carcinoma of the breast metastatic to the kidney. A clinically symptomatic lesion requiring surgical management..  68:1015-1020. 1991
  • Adjuvant intraperitoneal chromic phosphate therapy for women with apparent early ovarian carcinoma who have not undergone comprehensive surgical staging..  68:725-729. 1991
  • Statin immunolocalization in human brain tumors. Detection of noncycling cells using a novel marker of cell quiescence..  68:786-792. 1991
  • Hyperfractionated radiation therapy in brain stem tumors. Results of treatment at the 7020 cGy dose level of Pediatric Oncology Group study #8495..  68:474-481. 1991
  • Intraoperative electron beam radiation therapy for retroperitoneal soft tissue sarcoma..  68:278-283. 1991
  • A comparison of treatment outcomes for black patients and white patients with metastatic breast cancer. The Piedmont Oncology Association experience..  67:2850-2854. 1991
  • Estimate of breast cancer risk reduction with weight loss..  67:2622-2625. 1991
  • Stage I small cell carcinoma of the vulva treated with vulvectomy, lymphadenectomy, and adjuvant chemotherapy..  67:2415-2417. 1991
  • Obesity, body fat distribution, and sex hormones in breast cancer patients..  67:2215-2218. 1991
  • Intraoperative electron beam radiation therapy for recurrent locally advanced rectal or rectosigmoid carcinoma..  67:1504-1508. 1991
  • Obesity and body fat distribution and breast cancer prognosis..  67:523-528. 1991
  • A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer..  67:245-249. 1991
  • The role of elective lymph node dissection in the management of patients with thick cutaneous melanoma..  66:2522-2527. 1990
  • Primary carcinoma of the upper urinary tract. Effect of primary and secondary therapy on survival..  66:1919-1923. 1990
  • The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer..  66:431-436. 1990
  • Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer..  66:119-129. 1990
  • Breakout IV. Health professional concerns in the practice setting..  65:2413-2414. 1990
  • Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies..  65:439-445. 1990
  • Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma..  64:2203-2206. 1989
  • Hodgkin's disease presenting as myelofibrosis..  64:1720-1726. 1989
  • Cystosarcoma phyllodes. Effective therapy with cisplatin and etoposide chemotherapy..  63:2088-2092. 1989
  • Chemotherapy in the management of intraocular lymphoma..  63:1918-1921. 1989
  • Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates..  63:1065-1069. 1989
  • Electrocardiographic pseudo-myocardial infarct pattern in malignant cardiac disease..  63:958-962. 1989
  • Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma..  63:848-853. 1989
  • Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement..  63:742-747. 1989
  • Paraneoplastic limbic encephalopathy with testicular carcinoma. A reversible neurologic syndrome..  62:2248-2251. 1988
  • Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy..  62:1893-1898. 1988
  • Prognostic factors in head and neck melanoma. Effect of lesion location..  62:831-837. 1988
  • Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma..  62:84-91. 1988
  • Prevalence of dysplasia and cancer of the cervix in a nationwide, planned parenthood population..  61:2359-2361. 1988
  • Carcinomas in children. Clinical and demographic characteristics..  61:1046-1050. 1988
  • Analysis of results of radiation therapy for stage IB carcinoma of the cervix..  60:2195-2200. 1987
  • Oligodendroglioma. An analysis of the value of radiation therapy..  60:2179-2188. 1987
  • The development of Lhermitte's sign during cisplatin chemotherapy. Possible drug-induced toxicity causing spinal cord demyelination..  60:2170-2172. 1987
  • The histologic response of soft tissue sarcoma to radiation therapy..  60:1500-1504. 1987
  • The effect of the respiratory cycle on mediastinal and lung dimensions in Hodgkin's disease. Implications for radiotherapy gated to respiration..  60:1232-1237. 1987
  • Metastatic hemangiopericytoma with prolonged survival..  60:916-920. 1987
  • Lung cancer heterogeneity. Prognostic implications..  60:370-375. 1987
  • Immunologic and clinicopathologic features of common acute lymphoblastic leukemia antigen-positive childhood T-cell leukemia. A Pediatric Oncology Group Study..  59:2020-2026. 1987
  • A prospective study of squamous head and neck carcinoma. Immunologic aberrations in patients who develop recurrent disease..  59:1721-1726. 1987
  • Polyclonal polymorphic B-cell lymphoproliferative disorder with prominent pulmonary involvement in children with acquired immune deficiency syndrome..  59:1455-1462. 1987
  • Clinicopathologic correlations in the oligodendroglioma..  59:1345-1352. 1987
  • Results of treatment of stage IA and IIA Hodgkin's disease..  59:1107-1111. 1987
  • 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck..  59:887-890. 1987
  • Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience..  59:406-410. 1987
  • Differential retention of rhodamine 123 by avian sarcoma virus-induced glioma and normal brain tissue of the rat in vivo..  59:266-270. 1987
  • Adjuvant chemotherapy for advanced head and neck squamous carcinoma. Final report of the head and neck contracts program.  60:301-311. 1987
  • Results of treatment of stage 3A Hodgkin's disease..  59:27-30. 1987
  • Expression of epidermal growth factor receptors in human lung tumors..  58:2260-2263. 1986
  • Familial aggregation of melanoma, basal cell carcinoma, and gastric adenocarcinoma..  57:2230-2234. 1986
  • Adult respiratory distress syndrome after limited thoracic radiotherapy..  57:1941-1946. 1986
  • Rubidazone in the treatment of recurrent acute leukemia in children. A Pediatric Oncology Group Study..  57:1461-1463. 1986
  • The French-American-British (FAB) classification of leukemia. The Pediatric Oncology Group experience with lymphocytic leukemia..  57:1046-1051. 1986
  • A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates..  57:649-655. 1986
  • Obesity, non-protein-bound estradiol levels, and distribution of estradiol in the sera of breast cancer patients..  57:558-562. 1986
  • Characterization of renal neoplasms with monoclonal antibodies to leukocyte differentiation antigens..  57:251-256. 1986
  • Carcinoma of the cervix, stage III. Results of radiation therapy..  57:148-154. 1986
  • Thymoma and myasthenia gravis in a 4-year-old child. Case report and review of the literature..  56:2703-2706. 1985
  • An analysis of the presence of Fc receptors on bone marrow lymphoblasts in acute lymphoblastic leukemia. A Pediatric Oncology Group study..  56:1995-2000. 1985
  • Multiple myeloma and family history of cancer. A case-control study..  56:2133-2139. 1985
  • Criteria and definitions for response and relapse in children with brain tumors..  56:1824-1826. 1985
  • Female adnexal tumor of probable Wolffian origin with multiple recurrences over 16 years..  56:1456-1461. 1985
  • The glioblastoma multiforme in Georgia, 1977-1981..  56:894-897. 1985
  • Malignant melanoma and pregnancy..  55:1340-1344. 1985
  • Radionuclide lymphoscintigraphy with technetium 99m antimony sulfide colloid to identify lymphatic drainage of cutaneous melanoma at ambiguous sites in the head and neck and trunk..  55:1403-1413. 1985
  • Analysis of results of radiation therapy for Stage II carcinoma of the cervix..  55:956-962. 1985
  • Insular carcinoid of ovary associated with malignant mucinous tumors..  54:2273-2276. 1984
  • Low-dose preoperative radiation therapy for adenocarcinoma of the endometrium. A pilot study..  54:1002-1006. 1984
  • Atypical vaginal adenosis and cervical ectropion. Association with clear cell adenocarcinoma in diethylstilbestrol-exposed offspring..  54:869-875. 1984
  • Skin metastases confined to a field of previous irradiation. Report of two cases and review of the literature..  53:1864-1868. 1984
  • Childhood cancer and occupational radiation exposure in parents..  53:1637-1643. 1984
  • Correlation of serum tumor markers in advanced germ cell tumors with responses to chemotherapy and surgery..  53:1440-1445. 1984
  • Primary malignant fibrous histiocytoma of the lung. A clinicopathologic and ultrastructural study of five cases..  53:1124-1130. 1984
  • Sarcoma of bone and soft tissue following treatment of Hodgkin's disease..  53:232-236. 1984
  • Intratumoral consumption of indium-111 labeled platelets in a patient with hemangiomatosis and intravascular coagulation (Kasabach-Merritt syndrome)..  52:2256-2260. 1983
  • Lymphomas or leukemia presenting as ovarian tumors. An analysis of 42 cases..  52:1933-1943. 1983
  • Histologic, nuclear DNA, and human papillomavirus studies of cervical condylomas..  52:1705-1711. 1983
  • Stratification of risk factors in renal cell carcinoma..  52:899-903. 1983
  • Propionibacterium shunt nephritis in two adolescents with medulloblastoma..  52:330-333. 1983
  • Pancreatic islet cell carcinoma associated with multiple hormone secretion and pancytopenia. Evidence of a serum factor suppressing hematopoiesis..  51:1691-1696. 1983
  • Menstrual cycle-dependent variations of breast cyst fluid proteins and sex steroid receptors in the normal human breast..  51:1297-1302. 1983
  • The role of radiation therapy in the management of metastatic renal cell carcinoma..  51:614-617. 1983
  • Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma..  51:260-268. 1983
  • Hepatoid yolk sac tumor of the ovary (endodermal sinus tumor with hepatoid differentiation): a light microscopic, ultrastructural and immunohistochemical study of seven cases..  50:2355-2368. 1982
  • Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: a study of 25 cases..  50:2423-2432. 1982
  • CNS prophylaxis in acute lymphoblastic leukemia: comparison of two methods a Southwest Oncology Group study..  50:1031-1036. 1982
  • Metastatic thymoma with myasthenia gravis: complete remission with combination chemotherapy..  50:419-422. 1982
  • The natural history of colorectal carcinoma in adolescents..  49:1716-1720. 1982
  • Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen..  49:1236-1242. 1982
  • Erythroleukemia: a study of 15 cases and literature review..  49:101-108. 1982
  • Neurohormonal peptides in ovarian carcinoids: an immunohistochemical study of 81 primary carcinoids and of intraovarian metastases from six mid-gut carcinoids..  49:68-74. 1982
  • Quotient imaging with N-13 L-glutamate in osteogenic sarcoma: correlation with tumor viability..  48:1976-1981. 1981
  • Prognostic factors and treatment effects on survival in erythroleukemia: a retrospective study of 134 cases..  48:1101-1105. 1981
  • Comparative morphology of primary and secondary deposits of prostatic adenocarcinoma..  48:271-273. 1981
  • Breast carcinoma masquerading as primary ovarian neoplasm..  48:210-212. 1981
  • Immunoglobulin localization in benign and malignant lesions of the human mammary gland..  48:69-75. 1981
  • DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma..  46:2346-2348. 1980
  • Strumal carcinoid of the ovary: an analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid..  46:2019-2034. 1980
  • Sex steroid receptor analysis in human melanoma..  46:1463-1470. 1980
  • Clinical studies on the radioimmunodetection of tumors containing alpha-fetoprotein..  45:2500-2505. 1980
  • Endodermal sinus tumor of the pineal region..  45:2646-2651. 1980
  • A trial of outpatient chemotherapy for recurrent head and neck tumors..  45:2038-2041. 1980
  • Bilateral adrenal neuroblastoma..  45:2208-2212. 1980
  • Malignant effusions in recurrent breast cancer: steroid hormone receptor analysis of effusion fluid derived cells..  45:1609-1614. 1980
  • Ultrastructure of 16 cases of clear cell adenocarcinoma of the vagina and cervix in young women..  45:1615-1624. 1980
  • Congenital generalized fibromatosis with visceral involvement. A case report..  45:954-960. 1980
  • Primary amyloidosis, pure red cell aplasia, and Kaposi's sarcoma in a single patient..  44:1501-1503. 1979
  • Prognostic factors in metastatic and hormonally unresponsive carcinoma of the prostate..  44:763-775. 1979
  • Thyroid neoplasia following irradiation for medulloblastoma: report of two cases..  43:2232-2238. 1979
  • Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas..  42:1697-1704. 1978
  • Chronic lymphocytic leukemia..  42:941-945. 1978
  • Early deaths in newly diagnosed cases of pediatric acute leukemia: a Southwest Oncology Group Study..  42:781-786. 1978
  • I and i antigens on normal and leukemic leukocytes..  42:140-148. 1978
  • Hemidesmosome-like intercellular specializations in human meningiomas..  41:2242-2249. 1978
  • Fibrinogen kinetics in patients with neoplastic disease..  41:1113-1122. 1978
  • New presentation of alpha heavy chain disease: North American polypoid gastrointestinal lymphoma. Clinical and cellular studies..  41:1161-1169. 1978
  • The value of diagnostic aids in detecting pancreas cancer..  41:868-879. 1978
  • Ceruminous gland adenocarcinoma: a light and electron microscopic study..  41:545-553. 1978
  • Effects of continuous or discontinuous maintenance therapy on subsequent remission maintenance in childhood leukemia..  40:2005-2009. 1977
  • Prognotic significance of pretreatment proliferative activity in adult acute leukemia..  39:1603-1617. 1977
  • Effects of nitrogen mustard and splenectomy on mouse bone marrow colony formation in vitro..  38:1266-1271. 1976
  • Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study..  38:13-20. 1976
  • Benign vaginal rhabdomyoma: a light and electron microscopic study..  37:2283-2294. 1976
  • Glassy cell carcinoma of the cervix..  37:2238-2246. 1976
  • Cyclophosphamide-asparaginase- vincristine-prednisone induction therapy in childhood acute lymphocytic and nonlymphocytic leukemia..  37:1243-1247. 1976
  • Plasma dopamine-beta-hydroxylase in the diagnosis of neuroblastoma..  37:386-389. 1976
  • Unfavorable prognosis of acute leukemia in infancy..  36:1973-1978. 1975
  • Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study..  36:1598-1602. 1975
  • Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study..  36:1567-1576. 1975
  • Long-term results of reinforcement therapy in children with acute leukemia..  36:1552-1559. 1975
  • Adriamycin in the treatment of childhood acute leukemia. A Southwest Oncology Group study..  36:1223-1226. 1975
  • Fine structure of a radiation-induced osteogenic sarcoma..  36:1414-1425. 1975
  • Insular carcinoid primary in the ovary. A clinicopathologic analysis of 48 cases..  36:404-418. 1975
  • Comparison of prednisolone, vincristine, methotrexate, and 6-mercaptopurine vs. vincristine and prednisone induction therapy in childhood acute leukemia..  36:98-102. 1975
  • Ultrastructure of primary and metastatic ovarian carcinoids: analysis of 11 cases..  36:157-160. 1975
  • Management of recurrent melanoma of the extremity..  35:574-579. 1975
  • A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results..  34:suppl:1548-57. 1974
  • Clear-cell adenocarcinoma of the vagina and cervix in young females: analysis of 37 tumors that persisted or recurred after primary therapy..  34:606-614. 1974
  • Carcinoid metastatic to the ovary. A clinocopathologic analysis of 35 cases..  33:798-811. 1974
  • Clinical implications of aneuploid cytogenetic profiles in adult acute leukemia..  33:824-834. 1974
  • Proceedings: Immunologic similarities between fetal cell antigens and tumor cell antigens in guinea pigs..  33:376-383. 1974
  • Factors influencing survival in pediatric acute leukemia. The SWCCSG experience, 1958-1970..  32:1542-1553. 1973
  • Influence of trauma on the unusual distribution of metastases from carcinoma of the larynx..  29:466-471. 1972
  • Cytologic studies of glucose-6-phosphate dehydrogenase in malignancy..  21:1055-1060. 1968
  • Erratum: Smoking status and survival in the national comprehensive cancer network nonsmall cell lung cancer cohort (Cancer (doi: 10.1002/cncr.27824)).  119:1289-1290. 2013
  • Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer..  115:3376-3378. 2009
  • Disparities in breast carcinoma treatment in Asian/Pacific Islander women. A challenge to the provider..  95:2257-2259. 2002
  • Prognostic risk factors in low stage testicular germ cell tumors: unanswered questions regarding clinically useful prognosticators for extratesticular disease..  82:230-232. 1998
  • Palliative care and coping in patients with acute myeloid leukemia: Mediation analysis of data from a randomized clinical trial 2021
  • Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26-28, 2003, Philadelphia, Pennsylvania. 2004
  • Cancer: Introduction 2002
  • New applications of gemcitabine and future directions in the management of pancreatic cancer. 2002
  • GROWTH-REGULATION AND TRANSFORMATION OF OVARIAN EPITHELIUM 1993